Form 4: Nuo Therapeutics Director and 10% Owner Scott Pittman Acquires Additional Shares

Scott M. Pittman, a Director and 10% owner of Nuo Therapeutics, Inc., acquired 3,946 shares of common stock at $1.50 per share, increasing his direct beneficial ownership to 5,400,000 shares.

Summary

• Scott M. Pittman, a Director and 10% owner of Nuo Therapeutics, Inc. (AURX), acquired 3,946 shares of the company's common stock.
• The transaction occurred on July 30, 2025, at a price of $1.50 per share.
• Following this acquisition, Pittman directly beneficially owns a total of 5,400,000 shares of Nuo Therapeutics common stock.
• The transaction was approved by the Issuer's Board of Directors and Non-Employee Directors.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director and 10% owner generally indicates confidence in the company's future, which is a positive signal. The transaction was also board-approved.

Positives

• A Director and significant owner increasing their stake can signal confidence in the company's future prospects.
• The transaction was approved by the Board of Directors and Non-Employee Directors, indicating internal alignment.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4.

Industry Context

This Form 4 reports an individual insider transaction and does not provide broader industry context.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal of management confidence, potentially influencing investor sentiment.

Key Dates

Recommendation

The acquisition of shares by a director and 10% owner, Scott M. Pittman, signals confidence in Nuo Therapeutics. This insider buying, particularly when approved by the board, is generally viewed favorably by the market. However, without additional financial performance data or strategic updates, this single transaction primarily reinforces a 'hold' position, suggesting that existing investors might maintain their positions based on this positive signal, but it may not be sufficient to trigger a 'buy' recommendation for new investors.

Keywords

Nuo Therapeutics, AURX, Scott M. Pittman, Insider Trading, Form 4, Stock Acquisition, Director, 10% Owner, Common Stock, Beneficial Ownership